These in vivo findings further support the potential of ALDOA as a predictive biomarker for immunotherapy response in LUSC, and indicate that its upregulation may reflect a more immunogenic tumor microenvironment susceptible to checkpoint blockade. This evidence concerns the gene ALDOA and neoplasm.